Emission Patterns of Respiratory Pathogens

Pathogen Transmission Clinical Trial

Official title:

Emission Patterns of Respiratory Pathogens

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03491020
• Other study ID #: IRB00038054
• Status: Not yet recruiting
• Start date: July 2024
• Est. completion date: May 2025

Study information

• Verified date: July 2023
• Source: Wake Forest University Health Sciences
• Contact: Werner Bischoff, MD
• Phone: 336-716-5116
• Email: wbischof[@]wakehealth.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Airborne transmission represents one of the most rapidly spreading and dangerous dissemination mechanisms for pathogens. Public health strategies to prevent and control the often explosive outbreaks associated with such pathogens are: 1) vaccination and treatment, if available, 2) isolation and barrier precautions such as face masks, and 3) decontamination of the exposed areas and surfaces. A lack of understanding how these pathogens are transmitted hampers the ability to develop effective prevention measures. This study will be used to collect preliminary data of the emission patterns of respiratory pathogens.

Description:

Airborne transmission represents one of the most rapidly spreading and dangerous dissemination mechanisms for pathogens. The study team have been investigating bacterial and viral transmission routes and barrier precautions. In a recent clinical study, it was observed that Measles virus RNA was detected from a patient for at least up to 10 feet. In addition, the group has been studying barrier precautions (facemasks) for their ability to prevent the spread of aerosolized viruses. Finally, in a controlled lab setting the investigators have assessed the impact of environmental conditions (temperature, humidity) on pathogen transmission and the effect of UV-C light to prevent the spread of influenza. The purpose of this observational study is to describe the human aerosolization patterns of respiratory pathogens. The study team hypothesizes that the emission patterns of specific airborne pathogens varies between individual patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 55
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients >18 years of age admitted to the ED or an inpatient care unit of Wake Forest Baptist Medical Center (WFBMC)

• Positive

Exclusion Criteria:

• positive respiratory pathogen tests

Related Conditions & MeSH terms

• Pathogen Transmission

Locations

Country	Name	City	State
United States	Wake Forest Baptist Medical Center	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	particle size distribution patterns: ICU	This outcome measure will determine the particle size distribution patterns of the pathogen in the intensive care unit (ICU).	throughout study completion, up to 7 days
Primary	particle size distribution patterns: non-ICU setting	This outcome measure will determine the particle size distribution patterns of the pathogen in the non-intensive care unit (ICU).	throughout study completion, up to 7 days
Primary	quantities of the pathogen: ICU	This outcome measure will determine the quantities of the pathogen in the intensive care unit (ICU).	throughout study completion, up to 7 days
Primary	quantities of the pathogen: non-ICU setting	This outcome measure will determine the quantities of the pathogen in the non-intensive care unit (ICU).	throughout study completion, up to 7 days
Primary	spatial model: ICU	This outcome measure will establish a spatial model (1 foot vs. 3- feet vs. 8-10 feet) of airborne pathogen dispersal in the ICU.	throughout study completion, up to 7 days
Primary	spatial model: non-ICU setting	This outcome measure will establish a spatial model (1 foot vs. 3- feet vs. 8-10 feet) of airborne pathogen dispersal in a non-ICU setting.	throughout study completion, up to 7 days
Primary	correlation between the human aerosolization patterns and the severity of illness	This outcome measure is to determine the correlation between the human aerosolization patterns and the severity of illness (fever, respiratory symptoms, malaise) in individual participants.	throughout study completion, up to 7 days